Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...

Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

Now, scientists at Stanford University have found that a faulty genetic molecule could be responsible for the immune system misidentifying healthy tissue as a threat. The breakthrough study, published ...

Scientists at the Oklahoma Medical Research Foundation are one step closer to determining the genetic trigger for lupus in ...

If reading about these atrocities churns your stomach, reflect on what is going on before our eyes these very days ...

Eddie LeVert is mourning the loss of another one of his children after recently losing his 22-year-old daughter, Ryan LeVert, ...

An analysis of 2024 Google search data revealed the top health questions asked by Americans. A registered nurse provides ...

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.

In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...

Atkins Kroll, Inc. Guam donated $1,914 to the Lupus Awareness Group in commemoration of is 110-year anniversary, the company ...